IP
LCTX icon

Intellectus Partners’s Lineage Cell Therapeutics LCTX Stock Holding History

Intellectus Partners’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-40,247
Closed -$83K – 414
2018
Q3 		$83K Hold
40,247
– – 0.03% 302
2018
Q2 		$73K Hold
40,247
– – 0.03% 300
2018
Q1 		$95K Hold
40,247
– – 0.03% 290
2017
Q4 		$76K Hold
40,247
– – 0.03% 301
2017
Q3 		$100K Hold
40,247
– – 0.04% 301
2017
Q2 		$111K Hold
40,247
– – 0.05% 259
2017
Q1 		$121K Hold
40,247
– – 0.06% 220
2016
Q4 		$127K Buy
+40,247
New +$124K 0.07% 206

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
IA
IndexIQ Advisors New York $2.82B AUM 12.48% 1-Year Est. Return

Intellectus Partners's LCTX Position: Q4 2018 in Review

Intellectus Partners sold out of Lineage Cell Therapeutics (LCTX) in Q4 2018, closing a stake of 40,247 shares — an estimated $83K sold.

Intellectus Partners first reported a position in LCTX in Q4 2016 and held it in 8 quarters. The position peaked at $127K in Q4 2016. 105 funds tracked by Wall St. Rank hold LCTX as of Q4 2018.

  • Intellectus Partners reported no remaining Lineage Cell Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Intellectus Partners sold 40,247 Lineage Cell Therapeutics shares in Q4 2018, an estimated $83K.
  • Intellectus Partners first reported a position in Lineage Cell Therapeutics in Q4 2016 and held it in 8 quarters.
  • Intellectus Partners's Lineage Cell Therapeutics position peaked at $127K in Q4 2016.
  • 105 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2018.

Based on Intellectus Partners's 13F filing for Q4 2018, filed 14 Feb 2019.